Canada markets closed
  • S&P/TSX

    16,304.08
    +24.72 (+0.15%)
     
  • S&P 500

    3,465.39
    +11.90 (+0.34%)
     
  • DOW

    28,335.57
    -28.09 (-0.10%)
     
  • CAD/USD

    0.7620
    +0.0005 (+0.07%)
     
  • CRUDE OIL

    39.78
    -0.86 (-2.12%)
     
  • BTC-CAD

    17,216.45
    +288.71 (+1.71%)
     
  • CMC Crypto 200

    260.05
    -1.40 (-0.54%)
     
  • GOLD FUTURES

    1,903.40
    -1.20 (-0.06%)
     
  • RUSSELL 2000

    1,640.50
    +10.25 (+0.63%)
     
  • 10-Yr Bond

    0.8410
    -0.0070 (-0.83%)
     
  • NASDAQ

    11,548.28
    +42.28 (+0.37%)
     
  • VOLATILITY

    27.55
    -0.56 (-1.99%)
     
  • FTSE

    5,860.28
    +74.63 (+1.29%)
     
  • NIKKEI 225

    23,516.59
    +42.32 (+0.18%)
     
  • CAD/EUR

    0.6419
    -0.0019 (-0.30%)
     

Stocks in play: Bausch Health Companies Inc.

Baystreet.ca
·1 min read

And Allegro Ophthalmics, LLC (Allegro), a privately held biopharmaceutical company focused on the development of novel therapies that regulate integrin functions for the treatment of ocular diseases, announced today that Bausch Health (through its affiliate) has entered into an agreement to acquire an option to purchase all ophthalmology assets of Allegro (the "Option"), including global rights for risuteganib (Luminate®) , Allegro's lead investigational compound in retina, which is believed to simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as intermediate dry Age-related Macular Degeneration. Bausch Health Companies Inc. shares T.BHC are trading down $1.09 at $21.63.

Read: